Skip to main content

Table 4 Serum transfer and challenge with SHIV sbg

From: Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model

GROUP ID NO. VACCINE SEROLOGICAL RESPONSES
    Binding antibodies(log10 reciprocal titre)DOCa Virus neutralisation activity (50% virus inhibition log 10 titre) DOCa
    W61D rgp120 IIIB rgp120 SHIVW61D SHIVsbg
E C37 Serum from group A 3.9 3.9 2.4 <1
  C38   3.9 3.9 2.4 <1
  C39   4.3 3.6 2.5 <1
  C40   4.1 3.6 2.5 <1
  1. DOC = day of challenge.
  2. a = time of sampling.